ASCO 2018 | Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer

Name: Early RIBECCA results: ribociclib with letrozole for metastatic breast cancer
Uploaded: 2018-06-01T00:00:00Z
Duration: 1 min 40 s

Peter Fasching • 1 Jun 2018

ASCO 2018

Breast Cancer Letrozole Ribociclib

MONALEESA-2 MONALEESA-3 RIBECCA

In this interview, Peter Fasching, MD, from University Hospital Erlangen, Erlangen, Germany, discusses the design and the initial safety results of the Phase III RIBECCA trial (NCT03096847) investigating the efficacy and safety of ribociclib with letrozole for HR+ metastatic or advanced breast cancer. Dr Fasching then compares their results with the previous MONALEESA-2 (NCT01958021) and MONALEESA-3 (NCT02422615) studies, which also focused on the use of ribociclib for breast cancer. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.